PD-1 deficiency enhances Treg cell pro-tumor function Lim et al. demonstrate that Treg cells deficient in PD-1 occupy key spatial niches within the TME, with regulatory subsets organized near tumor ...

IBI363 has received two fast track designations (FTD) from the U.S. FDA and two breakthrough designations (BTD) from the ...

CDAI LDA (≤10) was achieved by 45% of 318 rosnilimab patients by Week 12, increasing to 69% (220 responders) across all doses ...

B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

Best-in-disease profile with JAK-like efficacy and monthly (Q4W) dosing in both three-month placebo-controlled and six-month​ blinded treatment period Favorable safety and tolerability, particularly ...

The USB-PD Programmable Power Supply (PPS) was implemented with USB PD3.0. With PPS, devices can gradually adjust the current ...

Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

A study has revealed why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumours and ...

Music has shown promise in easing symptoms of neurodegenerative disease — but don’t expect a prescribed playlist anytime soon ...

A study has revealed why some patients don't respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors and ...